Balloon catheter disruption of middle cerebral artery thrombus in conjunction with thrombolysis for the treatment of acute middle cerebral artery embolism

AJNR Am J Neuroradiol. 2007 Mar;28(3):513-7.

Abstract

Background and purpose: The goal of this study was to prospectively assess the feasibility, safety, and efficacy of balloon disruption of the middle cerebral artery (MCA) by using a deflated balloon catheter combined with an intra-arterial thrombolysis for the treatment of acute ischemic stroke.

Materials and methods: Seven consecutive patients with clinical findings of acute major-vessel stroke met our criteria and underwent balloon disruption of an MCA thrombus with a deflated balloon catheter. The balloon disruption was performed with a low-profile microballoon catheter. The microballoon was inflated in the distal carotid artery and then deflated and advanced just distal to the occlusion site in the MCA. Thereafter, an intra-arterial thrombolysis of the MCA was applied. The maximum time from the onset of symptoms to the start of treatment and maximum dosage of urokinase was 6 hours and 600,000 U. The outcome was classified as good for a modified Rankin Scale (mRS) score of 0 or 1, moderate for a score of 2 or 3, and poor for a score of 4 or 5.

Results: Complete recanalization was achieved in 5 patients and partial recanalization in 3. Three patients recovered to an mRS score of 0 or 1; 3, to scores of 2 or 3; and 1, to a score of 4. No patients died. There was no major intracerebral hemorrhage.

Conclusions: The penetration of the MCA with a deflated balloon catheter combined with an intra-arterial thrombolysis may be a safe and effective treatment for acute ischemic stroke.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Aged
  • Angioplasty, Balloon*
  • Cerebral Angiography
  • Combined Modality Therapy
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Humans
  • Infarction, Middle Cerebral Artery / diagnostic imaging
  • Infarction, Middle Cerebral Artery / drug therapy*
  • Male
  • Middle Aged
  • Pilot Projects
  • Retrospective Studies
  • Thrombolytic Therapy*
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / administration & dosage*

Substances

  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator